CSF2 and rheumatoid arthritis: Clinical trials assessing blockade of granulocyte macrophage colony-stimulating factor (GM-CSF) or its receptor (GM-CSFRα) have commenced in rheumatoid arthritis (RA), psoriasis, multiple sclerosis and asthma, with some encouraging RA data [1, 2].